Health Care [ 9/12 ] | Pharmaceuticals [ 57/75 ]
NASDAQ | Common Stock
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.
Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.28 Increased by +31.71% | -0.30 Increased by +6.67% |
| Aug 8, 24 | -0.44 Decreased by -22.22% | -0.40 Decreased by -10.00% |
| May 14, 24 | -0.36 Decreased by -20.00% | -0.44 Increased by +18.18% |
| Mar 13, 24 | -0.35 Decreased by -16.67% | -0.42 Increased by +16.67% |
| Nov 8, 23 | -0.41 Decreased by -10.81% | -0.36 Decreased by -13.89% |
| Aug 10, 23 | -0.36 Decreased by -2.86% | -0.37 Increased by +2.70% |
| May 10, 23 | -0.30 Decreased by -7.14% | -0.36 Increased by +16.67% |
| Mar 22, 23 | -0.30 Decreased by -11.11% | -0.39 Increased by +23.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 10.03 M Increased by +164.12% | -35.10 M Decreased by -124.54% | Decreased by -350.14% Increased by +14.98% |
| Jun 30, 24 | 8.05 M Increased by +391.70% | -17.09 M Decreased by -20.74% | Decreased by -212.19% Increased by +75.44% |
| Mar 31, 24 | 6.10 M Increased by +195.78% | -14.11 M Decreased by -9.99% | Decreased by -231.20% Increased by +62.82% |
| Dec 31, 23 | 6.10 M Increased by +N/A% | -13.81 M Decreased by -41.49% | Decreased by -226.57% Decreased by N/A% |
| Sep 30, 23 | 3.80 M Increased by +N/A% | -15.63 M Decreased by -51.36% | Decreased by -411.85% Decreased by N/A% |
| Jun 30, 23 | 1.64 M Increased by +N/A% | -14.15 M Decreased by -41.92% | Decreased by -864.10% Decreased by N/A% |
| Mar 31, 23 | 2.06 M Increased by +N/A% | -12.83 M Decreased by -56.01% | Decreased by -621.76% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -9.76 M Decreased by -33.40% | Decreased by N/A% Decreased by N/A% |